CeriBell, Inc. (CBLL) - Stock Analysis
Last updated: Jan 19, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Ceribell is a hot idea fueled by recent FDA 510(k) approvals for neurological devices, strong 31% YoY revenue growth, expanding market penetration, positive technical momentum with a 27% price rise, and favorable healthcare sector dynamics supporting near-term appreciation potential.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Exceptional gross-margin ⢠Persistent operating losses ⢠Rapid cash decline CBLL combines very high gross margins and low leverage with ample working capital but is undermined by sustained large operating losses, steep cash burn, and declining book value that signal significant near-term solvency and valuation risk.
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠Steady momentum ⢠Short-term dip Support Level: $20.00 Resistance Level: $23.43 (or $23.40â$23.50 zone) Over the last month CBLL has trended upward from about $20.18 to $21.94 with higher lows and steady momentum, but it faces resistance near $23.43 and showed a brief dip to ~$21.73 signaling short-term volatility.
Sentiment & News
Key News Insights: ⢠FDA Breakthrough designation ⢠Insider stock sales ⢠JPM growth focus CeriBell advanced its neuromonitoring platform with FDA Breakthrough Device designation for its AI LVO stroke solution, presented growth and EEG expansion plans at JPM, and saw notable insider stock sales.
AI Summary
Ceribell's FDA 510(k) and Breakthrough recognitions convert its story from pure R&D to a nearâterm commercialization play, but the investment now hinges on whether management can convert those regulatory wins into repeatable subscription revenue fast enough to stop the rapid cash burn and avoid dilutive financing. Investors should watch cash runway, opex/sales improvement, and conversion metrics (bookings/ARPU/renewal rates) over the next 2â4 quarters as the decisive catalysts for upside versus dilution.
Description
CeriBell, Inc. develops point-of-care EEG technology that uses AI to support detection and management of neurological conditions in acute care settings. Its Ceribell System pairs a bedside EEG platform with disposable headbands and portable recorders to enable rapid monitoring outside traditional neurodiagnostic labs. The company was incorporated in 2014, changed its name from Brain Stethoscope, Inc. in 2015, and is based in Sunnyvale, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 12 | Dec 19 | CBLL | CeriBell, Inc. | Ceribell is a hot idea fueled by recent FDA 510(k) approvals for neurological devices, strong 31% YoY revenue growth, expanding market penetration, positive technical momentum with a 27% price rise, and favorable healthcare sector dynamics supporting near-term appreciation potential. | Closed | +1.2% |